| Value | ₹37,649 Cr |
|---|---|
| Execution period | Early 2027 |
NSE filing, NSE: SUNPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Sun Pharmaceutical Industries Ltd: key numbers
- Share price
- ₹1,769.90
- Market cap
- ₹4,24,658 Cr
- Revenue (annual)
- ₹58,462 Cr
- Net profit (annual)
- ₹11,479 Cr
- P/E (TTM)
- 38.7×Sector 41.3×
- Promoter holding
- 52.68%-1.80% QoQ
- FII holding
- 14.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sun Pharmaceutical Industries Ltd
All →Sun Pharmaceutical Industries Price Movement Clarification
Sun Pharma said a 30 October 2026 news report concerned August 2026 developments, not new events. It confirmed no undisclosed material information explains the share price movement.
Sun Pharmaceutical Industries Annual General Meeting
Sun Pharma's postal ballot passed all seven special resolutions, including ESOP 2026 approval and borrowing and security limits. No monetary transaction is stated.
Sun Pharmaceutical Industries Earnings Call Transcript: Key Takeaways
Sun Pharma delivered resilient double-digit revenue growth despite U.S. specialty headwinds, masking underlying margin pressure from lower Lenalidomide sales.
Sun Pharmaceutical Industries Other Announcement
Sun Pharma's board appointed Deloitte as Statutory Auditors under mandatory rotation, effective from the FY 2026-27 AGM. This follows SRBC & CO's second five-year term completion.
Sun Pharmaceutical Industries Q2 FY27 Results: Net Profit ₹1,995 Cr, Down 36.2% YoY
Sun Pharmaceutical Industries Ltd reported revenue from operations of ₹16,199 Cr (+11.9% YoY) and net profit of ₹1,995 Cr (-36.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹1,995 Cr · -36.2% YoY
Sun Pharmaceutical Industries Regulatory Approval
Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.
Other acquisition announcements
All →John Cockerill India Acquisition Worth ₹257.8 Cr
John Cockerill India executed an amended SPA to acquire 100% of John Cockerill Metals International from its parent, at a revised price of €24.32 million. The consideration is partly cash and partly CCPS swap.
- Value
- ₹257.8 Cr
- Execution
- Allotment of CCPS within 15 days of RBI approval received 3 November 2026; conversion within 18 months of allotment
Apollo Micro Systems Acquisition
Apollo Micro Systems corrected its 2 November 2026 disclosure on acquiring shares of Premier Explosives. The acquired share count is now 1,39,77,911 and oversubscription is 5.45%.
Signatureglobal (India) Acquisition
Signatureglobal bought about 1.10 acres of land in Gurugram via a sale deed executed today. A further 1.88 acres from the 4.26-acre collaboration remains to be acquired.
Lloyds Metals & Energy Acquisition Worth ₹625 Cr
Lloyds Metals and Energy agreed to acquire Thriveni Earthmovers and Infra Private Limited for up to Rs 625 Crore in cash. The deal is expected to complete during FY 2026-27 in tranches.
- Value
- ₹625.0 Cr
- Execution
- FY 2026-27
Dalmia Bharat Sugar and Industries Acquisition Worth ₹216 Cr
Dalmia Sugar will invest up to Rs 216 crore via its UAE subsidiary for 51% of Eagle Agrotech. The funds support a Tanzanian sugar project.
- Value
- ₹216.0 Cr
- Execution
- Two (2) to Three (3) Years
- sugar crushing capacity
- 3500.0 TCD
Fractal Analytics Acquisition Worth ₹15.21 Cr
Asper.AI, a step-down subsidiary, acquired assets and liabilities of Pricing One SA for INR 15.21 crore. The deal adds revenue growth management talent and expands European presence.
- Value
- ₹15.21 Cr